Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
- Published: December 2010
The antidiabetics market is expected to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of Actos, with franchise sales reaching nearly $6 billion by 2019. Pipeline candidates will make up 30% of sales in 2019, with once-weekly GLP-1 agonists and new long-acting insulin analogs meeting success.
Reasons to Purchase
- Quantify the future size of the antidiabetics market from 2010-2019 and identify opportunities for new products
- Examine the future performance of leading antidiabetic brands and the growth of generics and insulin biosimilars
- Understand the barriers to uptake for novel antidiabetic agents